Navigation Links
For Treatment of Type 2 Diabetes, 89 Percent of Surveyed Endocrinologists Identify a Need for Additional GLP-1 Analogues and 71 Percent Say the Same About DPP-IV Inhibitors
Date:7/20/2009

WALTHAM, Mass., July 20 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that most surveyed clinicians identify a need for additional therapies from the GLP-1 analogue and DPP-IV inhibitor drug classes for the treatment of type 2 diabetes. In particular, surveyed physicians identify a greater need for new GLP-1 analogues, owing to the shortcomings of the current GLP-1 analogue, Amylin/Eli Lilly's Byetta. Surveyed physicians indicate that Byetta's shortcomings include frequent injections and high levels of nausea associated with treatment. Additionally, clinicians indicate that the shortcomings of Merck's DPP-IV inhibitor Januvia include less glucose-lowering compared to metformin and a lack of long-term safety data.

The new Physician & Payer Forum report entitled A Clinician and Payer Perspective on Changing Dynamics in the Diabetes Market: Is There Room for New GLP-1 Analogues or DPP-IV Inhibitors? finds that 89 percent of surveyed endocrinologists and 77 percent of surveyed primary care physicians (PCPs) indicate there is a need for additional GLP-1 analogue therapies. The report also finds that 71 percent of endocrinologists and 74 percent of PCPs indicate there is a need for additional DPP-IV therapies.

Similarly, 75 percent of surveyed managed care organizations' (MCOs) pharmacy directors indicate that additional agents are needed within the GLP-1 analogue class, and 70 percent indicate a need for additional agents from the DPP-IV inhibitor class. Forty-five percent of MCOs indicate that a novel antidiabetic agent's glucose-lowering efficacy compared with that of existing drugs carries the most weight in their decision whether to include the novel drug in their formulary and to what tier it should be assigned.

"Surveyed clinicians indicate that although the feature of Januvia that they would most like to see improved in future DPP-IV inhibitors is its glucose-lowering efficacy, a lower cost than Januvia would be a more persuasive factor in their decision to prescribe a novel DPP-IV inhibitor," said Decision Resources Analyst Christine Helliwell, Ph.D. "Additionally, MCOs say the cost of a novel DPP-IV inhibitor relative to the cost of Januvia will strongly influence tier placement. As a result, cost could provide an effective differentiating feature for novel DPP-IV inhibitors."

A Clinician and Payer Perspective on Changing Dynamics in the Diabetes Market: Is There Room for New GLP-1 Analogues or DPP-IV Inhibitors? is based on a U.S. survey of 77 primary care physicians, 72 endocrinologists and 20 MCO pharmacy directors. Their responses were compared to assess similarities and differences of opinion regarding clinical, economic and scientific factors.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources                    Decision Resources, Inc.
    Christopher Comfort                   Elizabeth Marshall
    781-296-2597                          781-296-2563
    ccomfort@dresources.com               emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. -Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments-
2. Lumenis UltraPulse TotalFX Treatment Featured on ABCNews 20/20 as a Secret Weapon for Treating for Burn Scars
3. Innovative Prostate Cancer Treatment Known as Sonablate(R) HIFU Now Available at Third Site in India
4. Addiction Treatment Will Help Make Health Reform Affordable, New Analysis Shows
5. Mylan Receives FDA Approval for Generic Version of Thyroid Deficiency Treatment Cytomel(R)
6. Cancer Patients Benefit From Speed, Accuracy of RapidArc Radiotherapy Treatments
7. Beijing Cancer Hospital Becomes First Hospital in Mainland China to Introduce Fast and Precise RapidArc Radiotherapy Cancer Treatments
8. New Outpatient Treatment for Heartburn-Related Problem Stops Esophageal Cancer Before It Starts
9. Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer
10. New Treatments for Alzheimers on the Horizon
11. Cadence Pharmaceuticals Announces Priority Review and Acceptance of NDA Submission for Acetavance(TM) for Treatment of Acute Pain and Fever
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... Texas (PRWEB) , ... September 20, 2017 , ... ... in the Orthodontics and Clear Aligner clinical and commercial support services market) has ... of Dentistry (PGSD) in Sydney, Australia. , The PGSD is the first ...
(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... In just ... Brain Booster has already been receiving positive feedback from customers trying the product for ... , Daily Brain Booster was developed by neurosurgeon Shawn Moore, MD, for everyone ...
(Date:9/20/2017)... , ... September 20, 2017 , ... ... of older Americans at risk of price gouging for their prescription drugs, according ... (TSCL) . “Because Medicare isn’t negotiating on our behalf, there’s no consistency in ...
(Date:9/20/2017)... ... , ... “RECYCLED Ezekiel's Plan for Freedom from ADDICTION”: A ... is the creation of published author, Bill Miller. Bill Miller has a ... more than a decade of addiction to prescription drugs. He has a ...
(Date:9/20/2017)... , ... September 20, 2017 , ... “Psalms of Humidity”: ... peace of mind and move the readers one step closer to God. “Psalms of ... realized that his mistakes that have been made within his life are the very ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... N.Y. , Sept. 6, 2017   PDI , ... announced it will host an educational session focused on ... bloodstream infection (CLABSI) prevention at the 2017 Annual Scientific ... which will take place at the Phoenix ... from Sept. 16-19, will also feature PDI,s ...
(Date:9/5/2017)... N.J. , Sept. 5, 2017  Getinge, ... has created a vibrant charitable donation program -- ... and support congenital heart defect research by The ... providers and the general public are encouraged to ... and submit the completed artwork to the gallery ...
(Date:9/1/2017)... 1, 2017  Bayer will present the latest research from ... Medical Oncology (ESMO) 2017 Congress, September 8-12 in ... preclinical and clinical data on Bayer,s marketed portfolio and late-stage ... "We value the ... cancer research at ESMO," said Carsten Brunn , Head ...
Breaking Medicine Technology: